CD8A and cancer: IL27 has been identified as a potentially useful target for anti-cancer clinical applications, probably due to its ability to regulate CD8+ T cells, natural killer cells, macrophages, and other immune checkpoints [28, 29]; our present findings regarding IL27 are consistent with these prior studies.